Jubaan Overview
Jubaan provides an advanced pre-screening system able to detect early warning signals of Gastrointestinal disorders, specifically the presence of adenomas in the colon. Having studied Microbiomes, specifically those found in the oral cavity and on the tongue, Jubaan, through a non-invasive process, brings to market a practical & intuitive answer in the form of a device called Gixam™ aimed at early-stage pre-screening. More importantly, Gixam™ aims to dramatically improve compliance rates for pre-screening exams. With Gixam™ Jubaan is set to change the manner the prevention battle and control of Colon Cancer is waged. Jubaan is currently part of the Alon Medtech incubator.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Jubaan’s Tongue Twister May Save Your Life
Jubaan, a healthcare technology company, has developed a non-invasive device called Gixam™ that can detect gastrointestinal disorders by scanning the tongue. The device uses spectral imagery algorithms to analyze color spectrums and identify signs of disease. With a specificity rate of 70%-78% and a sensitivity rate of 46%-67%, the Gixam™ offers accurate and immediate results for early detection of colorectal adenomas. Jubaan has mapped the tongues of over 13,000 patients and plans to expand its diagnostic capabilities to include other gastrointestinal disorders. The company aims to change the current paradigm by offering economic incentives to physicians and involving them in the screening and treatment process. The Gixam™ is currently undergoing clinical trials and hopes to receive FDA breakthrough device designation by the end of 2023.
CustomersPartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.94M |
| Last funding | $150K |
| Stage | A |
| Rounds | 4 |
| Investors | 4 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | jubaan.com/ |
Locations
Yokneam, Israel
Photos & Videos
No files yet
